For asthma and reversible bronchospasm associated with bronchitis and emphysema. ANDA 211832, held by Twi Pharms. Terbutaline Sulfate.
As of Nov 16, 2026, ANDA 211832 (Terbutaline Sulfate), held by Twi Pharms, was first approved by FDA on Jun 19, 2020, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Terbutaline sulfate is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 19, 2020 | Original application | Approved | None posted |
| Terbutaline Sulfate2.5MG · tablet;oral | Terbutaline Sulfate | Discontinued |
| Terbutaline Sulfate5MG · tablet;oral | Terbutaline Sulfate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters